Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Frontage Holdings's share price for the quarter that ended in Dec. 2023 was HK$2.32. Frontage Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 2,047 Mil. Therefore, Frontage Holdings's market cap for the quarter that ended in Dec. 2023 was HK$4,749 Mil.
Frontage Holdings's quarterly market cap
declined
from Dec. 2022 (HK$5,962 Mil) to Jun. 2023 (HK$4,113 Mil) but then
increased
from Jun. 2023 (HK$4,113 Mil) to Dec. 2023 (HK$4,749 Mil).
Frontage Holdings's annual market cap
declined
from Dec. 2021 (HK$8,103 Mil) to Dec. 2022 (HK$5,962 Mil) and
declined
from Dec. 2022 (HK$5,962 Mil) to Dec. 2023 (HK$4,749 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Frontage Holdings's Enterprise Value for Today is HK$3,313 Mil.
Frontage Holdings Market Cap Historical Data
The historical data trend for Frontage Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Frontage Holdings's Market Cap
For the Biotechnology subindustry, Frontage Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's Market Cap falls into.
Frontage Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Frontage Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (HKSE:01521) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Frontage Holdings Market Cap Related Terms
Thank you for viewing the detailed overview of Frontage Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Frontage Holdings (HKSE:01521) Business Description
Frontage Holdings Corp is a contract research organization providing integrated, scientifically driven research, analytical and development services. Geographically the group operates in both PRC and North America. The services provided in the North American segment, include Bioanalytical, CMC, DMPK and Safety and Toxicology services in the USA and Canada. The service offered in PRC includes Bioanalytical, Bioequivalence and CMC services in the PRC. Further, it also provides bioanalytical services, which are offered throughout the drug discovery and development process both in the United States and China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01521 has been successfully added to your 